Soligenix announces $1.5 million NIDCR SBIR grant supporting pivotal phase 3 trial
Soligenix announced the NIDCR has awarded Soligenix a SBIR grant of $1.5 million over two years to support the conduct of its Phase 3, multinational, randomized, double-blind, placebo-controlled study evaluating SGX942 (dusquetide) as treatment for severe oral mucositis. September 20, 2017